Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Drug Alcohol Depend. 2014 Dec 30;147:32–37. doi: 10.1016/j.drugalcdep.2014.12.019

Table 2.

All-cause and cause-specific mortality rates in older (≥50 years) opioid use disorder, younger (<50 years) opioid use disorder and older (≥50 years) no opioid use disorder VA patients, FY2000–2011

Older opioid use disorder
(n=36,608; 186,750 py)
Younger opioid use disorder
(n=23,662; 161,374 py)
Older no opioid use disorder
(n=36,608; 192,999 py)

Cause of deatha N (%) deaths CMR per 1,000 py
(95% CI)
N (%) deaths CMR per 1,000 py
(95 % CI)
N (%) deaths CMR per 1,000 py
(95% CI)
All cause 6,754 (100) 36.2 (35.3, 37.0) 2,632 (100) 16.3 (15.7, 16.9) 4,407 (100) 22.8 (22.2, 23.5)
Drug-related 659 (9.8) 3.5 (3.3, 3.8) 676 (25.7) 4.2 (3.9, 4.5) 79 (1.8) 0.4 (0.3, 0.5)
Accidental drug-related 562 (8.3) 3.0 (2.8, 3.3) 551 (20.9) 3.4 (3.1, 3.7) 61 (1.4) 0.3 (0.2, 0.4)
Suicide 149 (2.2) 0.8 (0.7, 0.9) 132 (5.0) 0.8 (0.7, 1.0) 75 (1.7) 0.4 (0.3, 0.5)
Violence 35 (0.5) 0.2 (0.1, 0.3) 49 (1.9) 0.3 (0.2, 0.4) 18 (0.4) 0.09 (0.06, 0.1)
Accidental injuries 193 (2.9) 1.0 (0.9, 1.2) 100 (3.8) 0.6 (0.5, 0.7) 113 (2.6) 0.6 (0.5, 0.7)
Cancer 1,518 (22.5) 8.1 (7.7, 8.5) 305 (11.6) 1.9 (1.7, 2.1) 1,240 (28.1) 6.4 (6.1, 6.8)
HIV 124 (1.8) 0.7 (0.6, 0.8) 92 (3.5) 0.6 (0.5, 0.7) 47 (1.1) 0.2 (0.2, 0.3)
Cardiovascular disease 1,711 (25.3) 9.2 (8.7, 9.6) 523 (19.9) 3.2 (3.0, 3.5) 1,367 (31.0) 7.1 (6.7, 7.5)
Liver-related 1000 (14.8) 5.4 (5.0, 5.7) 375 (14.2) 2.3 (2.1, 2.6) 349 (7.9) 1.8 (1.6, 2.0)
Chronic respiratory disease 411 (6.1) 2.2 (2.0, 2.4) 79 (3.0) 0.5 (0.4, 0.6) 254 (5.8) 1.3 (1.2, 1.5)
Respiratory infections 103 (1.5) 0.6 (0.5, 0.7) 26 (1.0) 0.2 (0.1, 0.2) 71 (1.6) 0.4 (0.3, 0.5)
Diabetes 181 (2.7) 1.0 (0.8, 1.1) 72 (2.7) 0.4 (0.3, 0.6) 199 (4.5) 1.0 (0.9, 1.2)
a

Causes of death are neither mutually exclusive nor exhaustive.

CMR: crude mortality rate. py: person-years. CI: confidence interval. Sex-disaggregated data are provided in the Supplementary Materials2.